<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-132823</identifier>
<setSpec>1888-6116</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pharmacological modulation of the glial scar for CNS injury repair</dc:title>
<dc:description xml:lang="en">Objective: To study the activity of neurostatin obtained enzymatically and purified using a new method, in cultures of cells involved in the formation of the glial scar. Material and methods: Neurostatin was obtained from the commercial ganglioside GD1b, using enzymatic Oacetylation, and was purified by a new simplified method. The activity of neurostatin was tested by an MTT proliferation assay in pericytes and rat microglial cells. Results: The activity of neurostatin obtained and purified by this new method was similar to the neurostatin obtained by the purification from mammalian brain. Neurostatin inhibited the PDGF-B growth factor induced proliferation of pericytes and LPS bacteria toxin induced proliferation of rat microglial cells at nanomolar concentrations. Conclusion: This new methodology to synthesize and purify neurostatin and its activity justify further studies to test its effect in animal models of CNS injuries and to evaluate its possible use as a therapy in patients with CNS injuries (AU)</dc:description>
<dc:creator>Nieto-Sampedro, M</dc:creator>
<dc:creator>Yanguas-Casás, N</dc:creator>
<dc:creator>Dámaso-Riquelme, E</dc:creator>
<dc:creator>Romero-Ramírez, L</dc:creator>
<dc:creator>Barreda-Manso, M. A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Estudiar la actividad de la neurostatina obtenida enzimáticamente y purificada mediante un nuevo método, en cultivos de células implicadas en la formación de la cicatriz glial. Material y métodos: La neurostatina se obtuvo mediante una reacción enzimática a partir del gangliósido GD1b comercial y se purificó con un método nuevo simplificado. La actividad de la neurostatina se probó en ensayos de proliferación con MTT en pericitos y microglía de rata. Resultados: La actividad de la neurostatina purificada fue similar a la obtenida mediante purificación a partir de cerebro de mamífero. La neurostatina inhibió la proliferación de los pericitos inducida por el factor de crecimiento PDGF-B y la proliferación de la microglía de rata inducida por la toxina bacteriana LPS a concentraciones nanomolar. Conclusión: La nueva metodología de obtención y purificación de la neurostatina y su actividad justifican su ensayo en modelos de lesión del SNC en animales, para evaluar su posible uso como terapia en pacientes con lesiones del SNC (AU)</dc:description>
<dc:source>Trauma (Majadahonda);25(4): 219-225, oct.-dic. 2014. tab, ilus</dc:source>
<dc:identifier>ibc-132823</dc:identifier>
<dc:title xml:lang="es">Modulación farmacológica de la cicatriz glial para la reparación de lesiones del SNC</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d33014^s22065</dc:subject>
<dc:subject>^d2525^s22026</dc:subject>
<dc:subject>^d33678^s22026</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d33678^s22021</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d9324^s22021</dc:subject>
<dc:subject>^d2904^s22074</dc:subject>
<dc:subject>^d7426^s22026</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d12345</dc:subject>
<dc:subject>^d2525^s22021</dc:subject>
<dc:subject>^d9324^s22026</dc:subject>
<dc:subject>^d2525^s22042</dc:subject>
<dc:subject>^d31306^s22026</dc:subject>
<dc:subject>^d31306^s22021</dc:subject>
<dc:subject>^d7426^s22075</dc:subject>
<dc:subject>^d35411</dc:subject>
<dc:subject>^d33014^s22002</dc:subject>
<dc:subject>^d2904^s22045</dc:subject>
<dc:subject>^d2904^s22075</dc:subject>
<dc:type>article</dc:type>
<dc:date>201412</dc:date>
</metadata>
</record>
</ibecs-document>
